|Day Low/High||114.05 / 116.04|
|52 Wk Low/High||72.14 / 136.26|
Analysts weren't shy to defend the company after Tuesday's earnings.
Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.
A roundup of biotech names with actions pending at the FDA in coming weeks.
The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.